The assessment of timepoint | ||||||
---|---|---|---|---|---|---|
Timepoint | Week 0 | Week 4 | Week 8 | Week 12 | Week 24 | Week 36 |
Incontinence episodes in 72 h | X | X | X | X | X | X |
Urgency incontinence episodes in 72 h | X | X | X | X | X | X |
Stress incontinence episodes in 72 h | X | X | X | X | X | X |
Other incontinence episode in 72 h | X | X | X | X | X | X |
Urinary frequency in 72 h | X | X | X | X | X | X |
Urinate episodes regarded as Grade 2 by PPIUS* in 72 h | X | X | X | X | X | X |
Urinate episodes regarded as Grade 3 by PPIUS in 72 h | X | X | X | X | X | X |
Nocturia episode in 72 h | X | X | X | X | X | X |
Water input in 72 h | X | X | X | X | X | X |
Pad consumption in 72 h | X | X | X | X | X | X |
ICIQ SF* questionnaire | X | X | X | X | X | X |
OAB-q SF* questionnaire | X | X | X | X | X | X |
PGI-I* score | X | X | ||||
PGSC* | X | X | X | X | X | |
Expectance evaluation | X | |||||
Blind effect evaluation | X | |||||
Dose of solifenacin taken | X | X | X | X | X | |
Safety evaluation of acupuncture | X | |||||
Adverse effect of Solifenacin | X | |||||
Other adverse events | X | |||||
Combination of medication | X | |||||
Adherence evaluation | X | |||||
Completeness of research | X |